The O 6 -methylguanine-DNA methyltransferase gene (MGMT) is methylated in several cancers, including gliomas. However, the functional role of cysteine-phosphate-guanine (CpG) island (CGI) methylation in MGMT silencing is still controversial. The aim of this study was to investigate whether MGMT CGI methyl ation correlates inversely with RNA expression of MGMT in glioblastomas and to determine the CpG region whose methylation best reflects the level of expression. The methylation level of CpG sites that are potentially related to expression was investigated in 54 glioblastomas by pyrosequencing, a highly quantitative method, and analyzed with respect to their MGMT mRNA expression status. Three groups of patients were identified according to the methylation pattern of all 52 analyzed CpG sites. Overall, an 85% rate of concordance was observed between methylation and expression (p , 0.0001). When analyzing each CpG separately, six CpG sites were highly correlated with expression (p , 0.0001), and two CpG regions could be used as surrogate markers for RNA expression in 81.5% of the patients. This study indicates that there is good statistical agreement between MGMT methylation and expression, and that some CpG regions better reflect MGMT expression than do others. However, if transcriptional repression is the key mechanism in explaining the higher chemosensitivity of MGMTmethylated tumors, a substantial rate of discordance should lead clinicians to be cautious when deciding on a therapeutic strategy based on MGMT methylation status alone. Neuro-Oncology 11, 348-356, 2009 (Posted to Neuro-Oncology [serial online], Doc. D08-00124, February 17, 2009
that there is good statistical agreement between MGMT methylation and expression, and that some CpG regions better reflect MGMT expression than do others. However, if transcriptional repression is the key mechanism in explaining the higher chemosensitivity of MGMTmethylated tumors, a substantial rate of discordance should lead clinicians to be cautious when deciding on a therapeutic strategy based on MGMT methylation status alone. Neuro-Oncology 11, 348-356, 2009 Keywords: CpG island methylation, expression, glio blastomas, MGMT E pigenetic alterations such as histone modifica tion and DNA methylation have been associated with tumor formation and progression. There is an increasing interest in aberrant promoter DNA meth ylation, as this mechanism is related to transcriptional repression and is involved in the disruption of key cel lular pathways. Among the genes with a promoter cysteinephosphateguanine (CpG) island (CGI) suscep tible to DNA methylation, the O 6 methylguanineDNA methyltransferase gene (MGMT) is one of the best stud ied. The currently investigated CpG sites were indeed found to be methylated in several cancers, notably in gliomas. 1 The study of MGMT promoter methylation status is of particular interest as MGMT encodes a DNA repair protein that removes alkylating lesions, thereby providing resistance to alkylating chemotherapeutic agents such as temozolomide. A methylated MGMT pro moter might thus reflect a "chemosensitivity state" to alkylating agents, as DNA methylation normally leads to transcriptional repression.
Hypermethylation of the MGMT promoter was found to be of favorable prognostic value in patients with glio blastomas (GBM) or lowgrade gliomas when treated with the alkylating agent temozolomide, with or without additional radiotherapy. [2] [3] [4] [5] [6] However, the role of 5' CGI hypermethylation in MGMT gene silencing is still con troversial. Several studies using cell lines have reported a relationship between MGMT gene expression and promoter methylation. [7] [8] [9] [10] One study in glioma cell lines even demonstrated a graded relationship between meth ylation and expression. 7 Many studies in primary human gliomas take for granted that MGMT DNA methylation is directly linked to MGMT transcriptional repression and therefore often focus on measuring MGMT DNA methylation as a marker of chemosensitivity to alkyl ating agents. However, to our knowledge, only one of the studies investigating both MGMT DNA methyl ation and MGMT expression (immunohistochemistry or mRNA) in gliomas actually showed a mutually exclusive presence of methylation or expression in a small series of eight human primary gliomas. 1 Other investigations showed only a partial correlation between these two measures [11] [12] [13] or no correlation at all. 14, 15 Notably, it was shown that MGMT DNA methylation and MGMT protein expression (immunohistochemistry) cannot be used interchangeably to predict survival for patients with malignant gliomas.
11 Another study of anaplastic gliomas showed a correlation between MGMT protein expression and survival but not between MGMT DNA methylation and survival. 14 The observed discordances between these measures point out the necessity of clari fying the exact relationship between MGMT CGI meth ylation and MGMT expression.
The MGMT promoter contains a 777bp CGI with 97 CpG sites. Studies of cell lines showed that differ ences in methylation levels were located within two large regions, 9,10 one of which contains the region that is most commonly investigated by the methylationspecific PCR assay (MSP). 1 The MSP region includes nine CpG sites that partially cover the first noncoding exon and the minimal enhancer. However, it is not known if these nine CpG sites are the sites that best reflect the status of expression. On the other hand, according to Pieper et al., 16 the changes in methylation between an MGMT expressing and nonexpressing cell line are focused in four CpG sites rather than being diffusely and uniformly distributed throughout the CGI. Two of these were approximately 130 nucleotides downstream of the tran scription start site (TSS) and included the region cur rently investigated by MSP, while the two others were approximately 200 nucleotides upstream of the TSS. 16 Taking these data together, it remains uncertain whether there are specific CpG sites, which are not necessarily located side by side, that influence the MGMT promoter activity level.
The aim of this study was to investigate whether MGMT CGI methylation reflects the expression of the gene in human GBM and to determine the CpG region whose methylation correlates best with the level of expression in primary tumors. Previously used assays assessing the methylation status of the MGMT CGI have provided mostly qualitative results or lowresolution quantitative results and considered the methylation state of only about 10 CpG sites. To investigate which CpG region is of interest, we quantitatively analyzed the methylation levels of 60 CpG sites for 54 GBM tumors by pyrosequencing, a highthroughput and reliable method, 17, 18 and correlated the results with the MGMT expression level of the tumors.
Materials and Methods

Patients
Patients were selected from our database containing clinical information regarding patients with a primary brain tumor that had been seen in our department since 2003. Inclusion criteria were (1) 18 or more years of age at onset, (2) histological diagnosis of GBM according to the WHO classification, (3) availability of cryopreserved tumor material, and (4) written informed consent for molecular analysis.
Samples and Bisulfite Treatment
DNA from frozen tumors and nonneoplastic brain tis sues (18 from epilepsy patients, 1 cerebellar gray cortex, 1 cerebellar white matter, and 4 from amyotrophic lat eral sclerosis patients) was extracted using a standard protocol (QIAmp DNA Mini Kit; Qiagen, Courta boeuf, France). We bisulfiteconverted 300 ng of DNA using the Gold DNA Methylation Kit (Zymo Research, Orange, CA, USA) according to the manufacturer's instructions.
Pyrosequencing
Quantitative DNA methylation analysis of the bisulfite treated DNA was performed by pyrosequencing or-in the case of several sequencing primers-by serial pyrose quencing. 18 Primers for PCR amplification, pyrose quencing, and primer extension reactions were pur chased from Biotez (Buch, Germany). Regions of interest were amplified using 30 ng of bisulfitetreated human genomic DNA and 5-7.5 pmol of forward and reverse primer, one of which was biotinylated. Sequences of oli gonucleotides for PCR amplification and pyrosequenc ing are given in 
Statistical Analysis
Statistical analysis was performed using the XLSTAT software (Addinsoft, Paris, France). The MannWhitney test was used to determine the relationship between meth ylation, as a quantitative variable, and expression, as a qualitative variable (low expression versus high expres sion relative to the average expression of eight controls). To analyze the methylation percentage as a qualitative variable (methylated vs. unmethylated), a cutoff value based on the methylation of the controls was chosen and defined as follows: cutoff 5 methylation average of con trols (from CpGs x to y) 1 2*STDEVP, where STDEVP is the standard deviation of controls from CpGs x to y. The chisquare test was used to determine the repartition between methylation and expression as qualitative vari ables. Twosided pvalues less than 0.05 were considered significant. The following variables were investigated: MGMT gene expression, MGMT promoter methyl ation status, and age. Hierarchical clustering was based on the degree of methylation (as a percentage) for each. Average linkage (unweighted pairgroup method using arith metic averages [UPGMA]) was used with squared Euclidean distance as an interval measure.
Results
MGMT CGI Methylation of GBM
The degree of CpG methylation in the MGMT CGI was investigated for 54 patients with GBM and for 24 nontu moral brain tissues. We analyzed a total of 68 CpG sites located in the promoter region of MGMT and extending at 95°C followed by 50 cycles of 30 s at 95°C, 30 s at the respective annealing temperatures (Table 1 ), and 20 s at 72°C, with a final 5min extension at 72°C. Then, 3-5 µl of the amplification products was incubated with 2 µl streptavidincoated Sepharose beads (GE Health care, Uppsala, Sweden) in 68 µl binding buffer (10 mM Tris, 2 M NaCl, 1 mM EDTA, 0.1% Tween 20; pH 7.6, adjusted with 1 M HCl). The template strands were purified and rendered singlestranded on a Pyrosequenc ing workstation (Pyrosequencing AB, Uppsala, Sweden). Beads were released into 12 µl annealing buffer (20 mM Tris, 2 mM Mgacetate; pH 7.6, adjusted with 4 M ace tic acid) containing 4 pmol of the respective sequencing primer (Table 1) , and sequencing primers were annealed to the target by incubation at 80°C for 2 min. Quanti tative DNA methylation analysis was carried out on a PSQ 96MD system with the PyroGold SQA Reagent Kit (Pyrosequencing AB), and results were analyzed using the QCpG software (version 1.0.9, Pyrosequencing AB).
Expression Analysis
Total RNA was isolated using an RNA extraction kit (RNeasy Lipid Tissue Mini Kit, Qiagen) according to the manufacturer's instructions. RNA quality was assessed using an Agilent 2100 Bioanalyser (Agilent Technologies, Massy, France). cDNA was prepared from each RNA sample (1 µg) using a combination of random primers (Promega, Lyon, France) and Moloney murine leukemia virus reverse transcriptase (Invitro gen, Cergy Pontoise, France). Realtime PCR was car ried out in a 25µl volume containing 5 µl of 20fold diluted cDNA, 600 nM of each primer, and 12.5 µl of 23 SYBR Green buffer (ABgene, Courtaboeuf, France). Values were normalized to the expression levels of the housekeeping gene ALAS (5aminolevulinate synthase). In parallel, the same experiments were performed on five nontumoral brain samples, also to normalize quan titative PCR values using the 2CT method. 19 Oligo into the first noncoding exon (CpGs at nucleotides -452 to 1195 relative to the TSS). Eight CpG sites situated at -452 to -399 relative to the TSS were highly meth ylated for both tumoral and nontumoral brain samples, as determined by pyrosequencing, suggesting that these CpG sites are situated outside of the promoter region that is susceptible to de novo methylation. This region was therefore excluded from further analysis. Moreover, analysis of glioma cell lines and tumors by cloning and sequencing showed that eight CpG sites situated at -90 to 169 corresponded to a methylationfree region in all samples (data not shown). Since this result indicates that this region has no impact on expression, we excluded it from our analysis. In total, 52 CpGs of the MGMT CGI that were potentially correlated with expression were analyzed further. Thirtyfive of these CpG sites were upstream and 17 were downstream of the TSS (Fig. 1) .
Three Groups of Patients Were Distinguished by Their Methylation Pattern among the 52 Analyzed CpG Sites
Hierarchical clustering of the methylation profiles of the 52 CpG sites provided strong evidence of two distinct patient classes (Fig. 2) . The first class grouped 18 patients (33%) with considerable methylation at almost all of the CpG sites tested (average range, 28%-55% methylation: group 1, methylated). The second class grouped the 36 other patients (67%) that had a lower global methylation level (average range, 4%-26%). This second class could be further separated into two subgroups, one showing a nonhomogeneous methylation pattern along the CGI (range average, 9%-26%: group 2, intermediate) with elevated methylation at only some CpG sites, and the other almost completely unmethylated (average range, 4%-9%: group 3, unmethylated). When integrated into the hierarchical clustering model, the control brain sam ples (average range, 6%-11%) clustered with the second class, between the intermediate group and the unmeth ylated group. Methylation patterns were found to be homogeneous between control brain samples along the CpG sites tested.
MGMT CGI Methylation and MGMT Gene Expression
MGMT gene expression was determined for all patients and for eight control brain samples. The MGMT expres sion level was relatively homogeneous among controls. Thirtyeight patients (70%) expressed lower levels of MGMT transcripts relative to the average expression of the controls, and 16 (30%) expressed higher levels of MGMT.
MGMT Expression Analysis of Methylated, Intermediate, and Unmethylated Groups
The three groups of patients (group 1, methylated; group 2, intermediate; group 3, unmethylated) were examined with regard to their expression level (low vs. high; Fig. 3 ). All patients in group 1 expressed a low level of MGMT. The specificity was lower for the other two groups. Twelve of 16 patients (75%) from group 3 expressed a high level of MGMT. Similarly, this relationship was not exclusive for patients of group 2, although a majority of them expressed a low level of MGMT (16 of 20, 80%). The relationship between methylation and expression as qualitative variables was statistically significant among the three groups of patients (p , 0.0001).
We also investigated whether the degree of expression within the group of lowexpressing or highexpressing patients was different according to their methylation profile. Markedly, no differences were found in the expression level among the lowexpressing patients in groups 2 and 3, or among the highexpressing patients in the same groups. The minimum methylation level observed within lowexpressing patients of group 2 was, on average, 9% for all 52 CpG sites analyzed. It thus appears that this level of methylation might be sufficient to suppress MGMT gene expression.
MGMT Expression Analysis for the Entire CGI and for Each of the 52 CpG Sites
Despite the fact that the relationship between MGMT expression and the three groups of patients, methylated (group 1), intermediate (group 2), and unmethylated (group 3), was unquestionable, it was nonexclusive.
Methylation of the entire set of 52 CpG sites and MGMT expression were analyzed as qualitative vari ables ( Table 2 ). The methylation status for each patient was determined according to the cutoff defined in "Materials and Methods." For all 52 CpG sites, the cut off was 10.65%. The majority of the methylated patients expressed a low level of MGMT (33 of 36, 91.6%), and the majority of the unmethylated patients expressed a high level of MGMT (13 of 18, 72.2%). Overall, concor dant results were observed in 85% of cases. We then examined whether a specific CpG site could best reflect the expression of MGMT. We analyzed each Fig. 2 ). We also aimed to identify a CpG region as a marker of expression since reducing the number of analyzed CpG sites could therefore facilitate clinical study setting. For this, we selected the CpG sites most correlated with expression, using methylation as a quantitative variable (CpGs at -395 to -352, -249 to -207, -186 to -172, -154 to -128, and 193 to 1153; p < 0.0006) and analyzed them with both methylation and expression as quali tative variables ( Table 2 ). The most concordant results were observed for CpGs -186 to -172 and CpGs 193 to 1153 with 81.5% concordance. The other CpG regions showed a larger percentage of discordant results due to an elevated percentage of unmethylated patients with low expression, up to 50% for CpGs -154 to -128.
In addition, we separately analyzed the region that is commonly studied by MSP (CpGs at 1118 to 1137 and at 1174 to 1195 for the methylated primers; Fig. 1 ). Fifty seven percent of patients were methylated. Although the majority of methylated patients expressed a low level of MGMT (27 of 31, 87%), unmethylated patients were found to express either a high (12 of 23) or low (11 of 23) level of MGMT. Overall, 28% discordant results were observed, demonstrating the analytical superiority of the novel regions identified in our study.
Discussion
This study demonstrates that MGMT CGI methylation correlates inversely with MGMT gene expression, but also points out that the relationship between methyl ation and expression is not absolute.
In the 54 analyzed GBM tumors, the methylation pat tern of the 52 CpG sites studied was found to be homo geneous (group 1, methylated, or group 3, unmeth ylated) in 63% of patients, whereas an intermediate methyl ation pattern, with some CpG sites being methylated and others not, was found in 37% of patients (group 2). Methylation of the whole 52 CpG sites correlated with expression with an 85% rate of concordance. To identify small CpG regions that best reflect MGMT gene expression, notably for a clinical study setting, we ana lyzed each CpG separately. Six isolated CpG sites (CpGs -228, -186, 195, 1113, 1135, and 1137) were of inter est, as well as two CpG regions (-186 to -172, and 193 to 1153), each with a minimum of 81.5% of concordant results between methylation and expression.
The four CpG candidates (-228, -186, 1125, and 1137) that could be linked to expression according to Pieper et al. 16 were among those with the most concor dant results (80%-81.5%) in our study. The region com monly investigated by MSP was not among the regions that best correlated with expression, although we found a rate of methylation (57%) similar to previous reports (45%-68%). 3, 4, 11, 14, 20 Promoter CGIs can present a differential pattern of methylation along the CGI, and some CpG sites may be more important than others with regard to expression. 21 In the case of MGMT, we identified five distinct regions associated with gene silencing, two of them reflecting MGMT expression better than the others. These regions bracketed a relatively methylationfree region of the CGI, which contained the minimal promoter, the TSS, and the first CpG sites of the noncoding exon. These results reinforce the fact that MGMT silencing is influenced by methylation of sites that are distant from the TSS. 9, 10, 16 Therefore, it seems that core regions do not necessarily include the TSS and the minimal promoter.
We examined whether transcription factor binding sites were present within particular CpG regions that correlated best with expression. Putative transcription factor binding sites were described initially by Harris et al. 22 when they cloned and sequenced the promoter region of MGMT. Proposed activator protein1 (AP1) and AP2 binding sites are located upstream of the CGI, and the majority of specificity protein 1 (Sp1) binding sites are within the methylationfree region. Remark ably, one CpG region associated with MGMT expres sion (-249 to -207) harbors an Sp1 binding site overlap ping CpG sites -246 and -242. However, neither these latter CpG sites nor the region -249 to -207 was among those that best reflect the MGMT expression. Very few reports have been dedicated to a functional analysis of potential MGMT transcription factors. Glucocorticoid responsive element and nuclear factor B (NFB) tran scription factor binding sites were reported 23, 24 but are not located at specific hypermethylated CpG regions associated with MGMT expression. The NFB tran scription factor binding sites are nonetheless located just upstream of the CpG region 193 to 1153.
The relationship between methylation and expres sion could be confirmed for 85% of the patients, at best. Other epigenetic mechanisms could explain the fact that some patients were unmethylated for the MGMT CGI but expressed a low level of MGMT, such as his tone modifications. 25 It is possible that MGMT DNA methylation plays only an indirect role in the regulation of MGMT expression. 16 Indeed, it has been suggested that DNA methylation in cancer could be a secondary process to an initial dramatic change in expression. 26, 27 MGMT gene silencing observed in nonmethylated patients could also be the result of some genetic alter ations. The MGMT gene is located in 10q26, a region that is frequently heterozygously lost in GBM. 28 How ever, no relationship was found between the expression of MGMT transcripts and the loss of 10q. The presence of mutations within the body of the gene has not been extensively explored. Only one report described MGMT gene mutations in 10 of 40 patients with esophageal cancer, 29 but whether these mutations affect enzymatic function or lead to modification of the expression level was not investigated. In contrast, some patients with a methylated MGMT CGI still expressed high levels of 
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MGMT. A recent study in cell lines and primary gliomas found that MGMT expression correlates with NFB activation, whereas no relationship was found between MGMT methylation and MGMT expression. 24 Further more, in HEK293 cells, overexpression of NFB/p65 increased MGMT expression despite the fact that the MGMT promoter was methylated in these cells.
Many retrospective clinical studies investigated either MGMT expression or MGMT methylation to determine the prognostic impact of MGMT. Both biomarkers have shown a prognostic association between MGMT status and outcome. Whereas MGMT protein levels seem to be largely controlled transcriptionally and not transla tionally or posttranslationally, 30 MGMT methylation does not always reflect gene expression as demonstrated in our and other studies, and it seems difficult to use one measure interchangeably with the other.
11,12,31 To date, MGMT promoter methylation status seems to be a robust prognostic predictor in GBM patients treated with alkylating chemotherapy. 4 Indeed, Gorlia et al. 32 recently recommended stratifying patients according to MGMT promoter methylation in future GBM tri als without further indication about MGMT expres sion. Hegi and colleagues showed that treatment with temozolomide led to a clear survival benefit in GBM patients with a methylated MGMT promoter, 4 whereas no association was found between MGMT expression as determined by immunohistochemistry and patient survival in the same population. 31 Conversely, Brell et al.
14 observed a prognostic impact of MGMT expres sion as determined by immunohistochemistry in 72 anaplastic glioma patients who received chemotherapy. This impact was not confirmed when analyzing MGMT promoter methylation status as a marker. These discrep ancies do not seem related to intratumoral heterogene ity since MGMT methylation and MGMT expression appear to be a global tumor phenomenon. 15, 33 Rather, it may be explained by observer variability relative to the immunohistochemistry technique 31 in addition to popu lation dissimilarities, grade of malignancy, and size of each cohort. Unfortunately, in our study, we could not determine which of the two biomarkers is clinically more relevant due to the limited number and short followup of our cohort. However, if transcriptional repression is the main mechanism explaining the higher chemosensi tivity of MGMTmethylated tumors, our data suggest that clinical decisions based on MGMT methylation status alone could leave behind a significant minority of unmethylated patients with low expression of MGMT who are potentially sensitive to treatment. Conversely, some methylated patients with high expression of MGMT could also be inadequately included.
To conclude, pyrosequencing appears to be a good and reliable technique to evaluate MGMT methylation status. However, the best MGMT methylation assay remains unsettled, 13, [30] [31] [32] and prospective comparisons of available assays are still needed. Furthermore, careful comparisons between methylation and expression stud ies should also be performed in future prospective clini cal trials to determine which information best predicts sensitivity to alkylating agents.
